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Female Hormones and Thrombosis
F.R Rosendaal, F.M. Heimerhorst, J.P. Vandenbroucke
Abstract—Exogenous hormones are used by more than a hundred million women worldwide äs oral contraceptives or for
postmenopausal hormone replacement Oral contraceptives mcrease the risk of venous thrombosis, of myocardial
mfarction, and of stroke The nsk is highest durmg the first year of use The venous thrombotic nsk of oral
contraceptives is high among women with coagulation abnormahties and with so-called third-generation contraceptives
(contaming desogestrel or gestodene) The nsk of myocardial mfarction does not appear to depend on coagulation
abnormahties or the type of oral contraceptive Hormone replacement therapy mcreases the risk of venous thrombosis
This nsk is also highest in the first year of use and among women with coagulation abnormahties The risk becomes
very high m women with a previous venous thrombosis Randomized tnals have not confirmed a beneficial effect of
postmenopausal hormones on the occurrence of myocardial mfarction (Arterioscler Thromb Vase Biol. 2002;22:201-
210.)
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Oral contraceptive use was first associated with thrombo-sis in 1961, with a report of pulmonary embohsm in a
nurse, who had just begun taking an oral contraceptive
contaming 100 μg mestranol for the treatment of endometn-
osis ' In 1963, the first case of myocardial mfarction m an
oral contraceptive user was reported 2 Estrogens mcrease the
risk of venous thrombosis when used äs oral contraceptives or
äs postmenopausal hormone replacement 3~5 A sirmlar effect
was observed in men when estrogens were used äs a treatment
of coronary disease6 or in sex-change treatment7 Recently, it
has been demonstrated that the piogestms in combination oral
contraceptives also affect the nsk of thrombosis 8~10
Thrombosis is a senous disorder Venous thrombosis,
although rarely fatal, often leads to a disablmg postthrom-
botic syndrome '' Artenal thrombosis may be fatal, äs myo-
cardial mfarction, or lead to disablmg sequelae m stroke
The nsk factors for thrombosis (Table 1) can be divided
into 3 groups of causes, accordmg to Virchow12 reduced
blood flow, changes m the vessel wall, and changes m the
composition of the blood In venous thrombosis, causes
related to stasis and blood coagulabihty are most important,
whereas in artenal disease, vessel wall changes stand out
Genetic nsk factors for venous thrombosis lead to hyperco-
agulabihty, whereas the acquired causes are either associated
with decreased flow (äs found in immobihzation, paralysis,
surgery, and plaster casts) or related to blood coagulation
(associated with the lupus anticoagulant, pregnancy, oral
contraception, and mahgnancies)
Oral Contraceptives
Content and Mode of Action
Oral contraceptives first became hcensed for birth control in
1959 Most oral contraceptives contam an estrogen and a
progestogen, with both contamed in each pill (monophasic
preparations) Over the years, the estrogen dose and the
progestogen compound have changed The first oral contra-
ceptive in the United States contamed 150 μg mestranol
Since then, the estrogen dose has been reduced, first to 50 μg
and then to 30 and to 35 μ-g, and some currently available
brands contam only 20 or 15 μg ethinyl estradiol The change
in progestogen concerned the chemical composition of the
progestogen rather than the dose because the progestogen
component prevents ovulation Early oral contiaceptives
contamed a first-generation progestogen, in the 1970s, the
second generation was used, and third generation progesto-
gens were used from the early 1980s in Europe and the 1990s
m the Unites States
Oral contraceptives act by preventmg ovulation through
the action of the progestogen, which suppresses lutemizing
hormone Estrogens are mainly needed to prevent break-
through bleedings With complete comphance, the failure rate
is <1%
Ethinyl estradiol is a synthetic shghtly altered version of
the naturally occumng estiadiol, which is mactive when
taken orally In the absence of a formal classification System
of progestogens, these are usually grouped into "geneiations"
that are based on when they were first produced First
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High levels of factor VIII
APC resistance in the absence of FVL
High levels of factor IX
High levels of factor XI
High levels of TAFI
FVL indicates factor V Leiden; TAFI, thrombin-activatable fibrinolysis inhibitor.
generation progestogens include norethisterone, norethyno-
drel, lynestrenol, and ethynodiol acetate. The second gener-
ation includes norgestrel, levonorgestrel, and norgestrione.
The third generation includes desogestrel, gestodene, and
norgestimate. Norgestimate is often grouped among second-
generation progestogens, because after uptake, it is partly
converted to levonorgestrel. Cyproterone acetate (not avail-
able in the United States) and drospirenone are not yet
categorized.
Oral Contraceptives and Venous Thrombosis
An early comparative study was based on information gath-
ered by the Royal College of General Practioners.13 From a
comparison of patients and healthy controls (case-control
study), it was reported in 1967 that oral contraceptive users
had a 3-fold increased risk of venous thrombosis compared
with nonusers. This was confirmed by other studies from the
United Kingdom and the United States, with relative risk
estimates ranging between 4 and II.14-17 In the 1970s, large
prospective follow-up studies again confirmed these find-
ings.18-20 When we combine all studies performed until the
1990s, a 3-fold increased risk results.21 These studies also
showed that oral contraceptives conferred an immediate
effect: the risk did not become larger with longer duration of
use and disappeared when oral contraceptives were
discontinued.
These early studies were performed when objective testing
for venous thrombosis was not widely used. We now know
that the clinical diagnosis of venous thrombosis suffers from
a high rate of false positives22·23; therefore, these studies
probably had substantial misclassification. This is supported
by studies that compared the risk by level of certainty of
diagnosis and that usually found higher risk estimates. 14~
i6,i9.2o,24 Therefore, the risk of oral contraceptives may have
been underestimated in the older studies.
In recent studies, performed in the 1990s, a 2- to 6-fold
increased risk for venous thrombosis was found in oral
contraceptive users.25-28 In a Dutch study, the absolute risk
was estimated at 0.8 per 10 000 per year among nonusers and
3.0 per 10 000 per year among oral contraceptive users.25 In
a study in the United Kingdom, a similar annual risk, 2.0 per
10 000 users, was found.29 These numbers indicate a low
absolute risk; ie, several thousands of women would need to
abstain from oral contraceptives to prevent l case of throm-
bosis per year (numbers needed to treat). Because oral
contraceptives are the most reliable form of reversible con-
traception, it has even been argued that such a policy might
lead to an increase in venous thrombotic events through an
increase in unintended pregnancies.21 Nevertheless, because
oral contraceptives are so widely used, they are responsible
for a large share, if not the majority, of all venous thromboses
in young women.
Diagnostic Suspicion and Referral Bias
The so-called referral or diagnostic suspicion bias is the
hypothesis that has been brought forward to explain the
absence of a reduction of the risk of thrombosis associated
with the use of oral contraceptives since the 1960s. This bias
involved women presenting with leg complaints being re-
ferred for thrombosis especially if they used oral contracep-
tives, because doctors were aware of this association. If,
subsequently, women with thrombosis were compared with
healthy women, there would be an excess of oral contracep-
tive users among patients, spuriously suggesting an increased
risk.
Two studies compared women who were referred for
diagnostic tests that were positive for thrombosis with women
who were referred for the same tests, which proved negative
for thrombosis.30·31 In this setting, referral bias would have
acted similarly for both groups. The relative risks for throm-
bosis associated with oral contraceptive use found in these 2
studies were 6.430 and 3.931; ie, they were similar to those
found in studies with population controls. This demonstrates
that the risk of venous thrombosis is still present and cannot
be explained by referral bias.
Effect of Lowering of the Estrogen Dose
The first oral contraceptives contained doses of 100 to 150 μg
mestranol or ethinyl estradiol, which over time has been
reduced to 50 μ-g and, subsequently, to 30 μg and, even in
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Relative risk (RR) for venous thrombosis m oral contraceptive
use The RRs (users vs nonusers) are shown from studies pub-
lished between 1967 and 1989, with 95% Cis A relative risk of
1 mdicates equal nsks, and a relative risk >1 indicates a higher
risk for users than for nonusers The studies mclude case-
control studies,1315-17158-162 follow-up studies,18-20163-165 and 1
randomized controlled tnal16e Some figures were estimated
from data m the original articles (repnnted with permission from
Thrombosis and Hemostasis)
some of the newest brands, to 20 μg ethinyl estradiol One of
the aims of this dose reduction was to lower the risk of
thrombosis However, when we look at the risk estimates
from studies published from the 1960s to the 1990s, such a
nsk reduction appears not to be present (Figure) In several
direct compansons, a lower nsk with a lower estrogen dose
has been found 20 24 32 In the most recent of these studies, a
10-fold mcreased nsk compared with that for nonusers was
found for users of oral contraceptives contammg >50 μg
ethinyl estradiol, and there was a 4-fold mcreased nsk for
contraceptives contammg <50 μg ethinyl estradiol32 Several
other studies have not confirmed a lowenng of risk with
lower estrogen doses in the Leiden Thrombophiha Study, a
direct companson of oral contraceptives that contamed either
50 μg or 30 μg ethinyl estradiol and the same progestin
(levonorgestrel) found no difference8 There are no data
involving oral contraceptives contammg 20 μg ethinyl
estradiol
Effect of Changes in the Progestogen Content
Although estrogens have been known to be associated with
the nsk of thrombosis for many decades, it has always been
considered that the progestogens in these combination prep-
arations did not affect nsk at all However, m 1995, 3 studies
published simultaneously reported an increase of thrombosis
in women usmg oral contraceptives contammg the newest
progestins, ιέ, desogestrel and gestodene (also known äs
third-generation progestins) 8~10 Most subsequent studies
confirmed this fmdmg,293133~37 but some did not38 41 A
recent meta-analysis combmmg the evidence from all studies
found an overall l 7-fold mcreased risk for users of third-
generation oral contraceptives compared with second-
generation users 42 Interestmgly, the relative nsk was >2-fold
mcreased in studies funded through public agencies but only
l 3-fold m studies sponsored by pharmaceutical compames
producing third-generation contraceptives42 The risk for
third-generation users was higher durmg the early phases of
use but remamed 2-fold mcreased compared with the nsk for
second-generation users of oral contraceptives durmg long-
term use
In the debate after the publication of the original studies,
Potential biases have been put forward äs alternative expla-
nations 39 40 43~52 Careful consideration, reanalyses of the
original studies, new studies, and an extensive comprehensive
look m the meta-analysis led to the conclusion that bias could
not explain the observations of an mcreased nsk 42 53~56 An
mdependent expert committee convened by the World Health
Orgamzation concluded that third-generation contraceptives
camed an mcreased nsk of venous thrombosis 57
Strang support for the epidemiological fmdmgs came from
a biochemical study in 1997 showmg that the plasma of
women usmg third-generation contraceptives was tilted to-
ward a prothrombotic state, äs measured with a newly
developed assay 58 This assay measures sensitivity to acti-
vated protem C (APC), but unlike the Standard APC-
resistance lest, which is based on the activated partial throm-
boplastm time, it is based on clottmg activation through the
extnnsic pathway by tissue factor58-60 In this assay, the
endogenous thrombin potential (ETP) is quanüfied, ETP is
defmed äs the time integral of free thrombin concentration,
usually derived from residual levels of amidolyüc activity,
determmed in the presence and absence of added APC,
yieldmg an APC-sensitivity ratio58 This APC-resistance test
proved sensitive in detectmg factor V Leiden but was far
more sensitive to exogenous factors than was the activated
partial thromboplastin time-based APC-resistance test 61 62 In
the ETP-based APC-resistance test, use of third-generation
oral contraceptives led to prothrombotic abnormahties com-
parable to those found in heterozygous factor V Leiden 58
This result was confirmed by a randomized crossover tnal of
second- and third-generation oral contraceptives 63 Differen-
tial effects were observed on procoagulant, anticoagulant, and
fibnnolytic factors 63-66 The main effects were a more pro-
nounced APC resistance in the ETP-APC test äs shown
before,63 a large mcrease in factor VII levels,54 and sharp
decreases m free and total protem S,66 which was subse
quently confirmed in another study 67 These are all changes
that would be expected to lead to an mcreased nsk of
thrombosis
Other Risk Factors and Oral Contraceptive Use
For climcal purposes, it is important to consider whether
some women have a higher risk of thrombosis when usmg
oral contraceptives than do others For venous thrombosis,
nsk factors to be considered mclude a personal or family
history of venous thrombosis and prothrombotic abnormah-
ties, le, factor V Leiden, prothrombm 2021OA, and deficien-
cies of protem C, protem S, or antithrombm
A previous thrombosis is, by far, the strengest predictor for
venous thrombotic events In most studies, the recurrence rate
after 3 months of anticoagulation is between 2% and 5% per
year 68~73 It is currently unclear whether the recurrence rate is
higher for individuals with coagulation abnormahties 7174~82
Oral contraceptives are often withheld after a first episode of
thrombosis, therefore, there are no firm data on the recurrence
nsk with contmued use
In famihes with deficiencies of protem C, protem S, and
antithrombm, the nsk of first thrombosis appears to be
mcreased m women who have l of these abnormahties and
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who use oral contracepüves, with a very high nsk in anti-
thrombm deficiency 83 Among relatives of unselected pa-
tients with l of these deficiencies, oral contraceptive use
further mcreased thrombotic nsk 6- to 8-fold83 Although
deficiencies of natural anticoagulants are rare (l 5000 to
l 250), factor V Leiden and prothrombm 2021OA are found
m 2% to 7% percent of most Caucasian populations 84~86
Caniers of factor V Leiden who use oral contraceptives have
a 20- to 30-fold mcreased nsk of developing venous throm-
bosis,17 38 and there is an even much higher nsk for homozy-
gous factor V Leiden camers usmg oral contraceptives87 88
Prothrombm 2021 OA is a mild nsk factor for thrombosis,
mcreasmg nsk 2- to 3 fold However, in combination with
oral contraceptives, the nsk appears to be higher, with a
16-fold mcreased nsk compared with that for noncarner
nonusers 31i
High levels of factor VIII are a common, moderately strong
risk factor for venous thrombosis 8C) 9I In combination with
oral contraceptives, no synergistic etfect has been observed,
le, the combination of high levels of factor VIII and oral
contraceptive use led to no higher risk than did the sum of the
separate effects 92
The risk of thrombosis in users of oral contraceptives is
highest durmg the tirst year of use 17 91 This is particularly the
case among women with prothrombotic defecls,93 which are
mdicative of a high thrombosis potential94 m these women, in
whom a small turther increase in nsk is sufficient to bring
about thrombosis However, the nsk is also higher in the first
year than durmg prolonged use m women without known
prothrombotic defects, suggestmg the presence of as-yet-
umdentified nsk factors 93
Oral Contraceptives and the Risk of
Arterial Disease
The first report of an association between oral contraceptive
use and myocardial infarction was pubhshed m 1963,2 an
association with ischemic stroke was first pubhshed m
1968,95 and an association with hemorrhagic stroke was
pubhshed m 1973 96 The association with arterial disease was
confirmed m a series of studies 97 104 Recently, the multi-
center study by the World Health Organization (WHO)
showed a 5-fold mcreased risk of myocardial infarction with
currently used oral contraceptives,105 äs well äs a 3-fold
mcreased nsk of ischemic stroke106 and a l 5- to 2-fold
mcreased risk of hemorrhagic stroke 107 It has repeatedly
been shown that the risk of myocardial infarction is particu-
larly high among users of oral contraceptives who also smoke
or have hypertension57" Among women without major
cardiovascular risk factors, the risk of myocardial infarction
seems very low,55 and in some studies, no excess nsk was
observed at all l08
Over the years, the dose of estrogen has been lowered, and
the progestogen has been modified, mainly m an effort to
reduce the risk of arterial disease among users of oral
contraceptives It is unclear whether the lower nsk of myo-
cardial infarction associated with the use of oral contracep-
tives in several of the newer studies is the result of the
lowermg of the estrogen dose or of selective prescnption to
women without cardiovascular risk factors The WHO study,
which showed a large effect of blood pressure screenmg,
suggests that the latter played a major role im
Contraceptives contammg third-generation progestins
desogestrel and gestodene have a favorable effect on the lipid
profile, with a slight mcrease in HDL Several small studies
had conflictmg results regarding whether the nsk of myocar-
dial infarction would be lower with these contracep-
tives OS 109 no τ wo recent large studies on myocardial infarc-
tion in young women and the use of oral contraceptives failed
to demonstrate a benefit for third-generation prepara-
tions '" "2 Prothrombotic abnormahties, which play a major
role m the etiology of venous thrombosis, at most mildly
increase the risk of myocardial infarction,113-115 and this nsk
is only in women with major cardiovascular nsk factors, m
particular, smoking There does not seem to be an enhanced
nsk of myocardial infarction with contraceptive use in
women with these mutations 112
Hormone Replacement Therapy
The use of postmenopausal hormone Substitution has become
widespread in recent decades 116 Besides rehef from meno-
pausal complamts, hormone replacement is prescnbed to
reduce the progression of osteoporosis and the development
of cardiovascular disease Several observational studies
showed impressive cardiovascular benefits, le, a halvmg of
the risk of cardiovascular events and deaths n7-123 Because
women who used hormone replacement usually had a better
cardiovascular nsk profile than did nonusers, selection blas
offered an alternative explanation for the apparent bene-
fits l24 126 Therefore, several randomized trials have been
performed or are in progress
Content and Types of Hormone
Replacement Therapy
Most preparations nowadays contam an estrogen and a
progestm, this combination was mtroduced after it was shown
that unopposed estrogen therapy increases the nsk of endo-
metnal cancer (reviewed in Grady et al116) Estrogen-only
hormone replacement is still used m women without a Uterus
Conjugated estrogens m oral preparations are extracted from
pregnant märe urme, the progestm compound is usually
medroxyprogesterone acetate Micromzed estradiol is avail-
able in tablets or can be dehvered transdermally (patches),
percutaneously by gels, or subcutaneously by pellets 127
Hormone Replacement Therapy and Risk of
Venous Thrombosis
In an early study of adverse effects of estrogen replacement
therapy, a slight risk increase of venous thrombosis was
observed 128 This was not confirmed in subsequent stud-
ies,129-131 and the idea that estrogen replacement could cause
venous thrombosis was disrmssed äs '"medical supersti-
tion "n2 However, from 1996 onward, a series of studies has
demonstrated that hormone replacement users have a 2- to
4-fold mcreased nsk of venous thrombosis 3~5
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Risks of venous thrombosis are shown for carners of factor V Leiden, users
of either oral contraceptives or hormone replacement therapy, or both relative
to noncarners nonusers25142
Risk of thrombosis is highest in the first year of
use,34 134 135 138 and m some studies,134 135 138 but not in
all,3 n7 the nsk was limited to the first year Oral use and
transdermal patches mcrease the nsk of thrombosis,114 ns and
an association with thrombosis has been found for conjugated
estrogens äs well äs for estradiol m 138
Why did the early studies not detect the thrombosis nsk
associated with thrombosis7 This may have been caused by
less reliable diagnostic methods m the past, which may have
been adequate to detect the nsk of the then high-dosed oral
contraceptives but not of the lower estrogen dose in hormonal
replacement therapy The less widespread use of hormone
replacement may also have been a factor
Hormone Replacement Therapy and
Arterial Thrombosis
The beneficial effects of postmenopausal hormones noted in
observational studies have not been confirmed in the 2
randormzed tnals conducted to date One study, includmg
women with pnor coronary disease, found no benefit of
hormone Substitution over placebo dunng 5 years of follow-
up,139 whereas an mcrease in venous thrombosis was reported
from this trial136I37 Post hoc analyses showed that the artenal
events were clustered m the first year, with lower nsks in the
active group than m the placebo group in years 4 and 5 13'J
The other placebo-controlled trial is an ongoing study of
nearly 30 000 women without pnor disease I4° In the first 2
years of follow-up in that study, an excess of myocardial
infarction and venous thrombosis occurred in the treatment
group
Effect of Other Risk Factors
One randomized trial of hormone replacement therapy has
been conducted among women with a previous deep vein
thombosis l27 The study was termmated prematurely and
showed a high rate of recurrence of 85% per year in the
treatment group versus only l 1% in the placebo group 127
The highei nsk of venous thrombosis m the first year
suggests that for hormone replacement therapy, äs for oral
contraceptives, some women are at higher risk, probably
because of prothrombotic abnormahties In the Oxford case-
control study, a high nsk was observed in women who were
APC resistant and used hormone replacement therapy λ 141 In
a subsequent genetic analysis, U was confirmed that the APC
resistance m these women was based on carrymg factor V
Leiden Whereas factor V Leiden alone increased the risk
4-fold and hormone replacement increased the nsk only
3-fold, the combination led to a 15-fold increased nsk 142
Table 2 shows the effect of factor V Leiden in combination
with either oral contraceptives or hormone replacement ther-
apy on the risk of venous thrombosis
For the artenal side, the increased nsk m the first year in
the randomized trials suggests a similar genetic predisposi-
tion in some women Further evidence has come from a study
reporting that in women with prothrombm 20210 A, the use of
hormones increases the risk of myocardial infarction, in
particular among hypertensive women, with an 11-fold in-
creased nsk 143
Biological Mechanism of the Effect of Hormones
on Thrombotic Risk
Estrogens have many different effects on the coagulation
System62144 14V These include increases in the levels of
procoagulant factors VII, X, XII, and XIII and reductions m
the anticoagulant factors protein S and antithrombin These
changes predict a change toward a more procoagulant state
(which is confirmed in studies examimng global tests, such äs
APC resistance or thrombin generation),6'-6466 which is not
counterbalanced by an increased übnnolytic activity 6<i The
estrogens in hormonal replacement therapy have hemostatic
effects similar to those m oral contraceptives I4S l49
It is currently unclear how these effects are brought about
at the molecular level of the estrogen receptor It is hkely that
these etfects at the cellular level are also under genetic
control, because the hemostatic System of some women
appears to be more sensitive to the effect of estrogens than
that of other women no It is also unclear how estrogens and
progestms mteract in their effect on thrombosis, for instance,
in the higher nsk ot oral contraceptives contaming a third-
generation progestin It appears that estrogens are prothrom-
botic rather than proatherogenic, which explams the absence
of an increased nsk in former users
Other Hormones
Selective estrogen receptor modulators, such äs tamoxifen
and raloxifene, have antiestrogenic effects on breast and
endometnal tissue and are used m the treatment and preven-
tion of breast cancer However, these drugs have estrogenic
effects on blood clottmg A placebo-controlled trial of tamox-
ifen m nearly 14 000 women with an increased risk of breast
cancer showed increased nsks of ischemic stroke (relative
nsk l 6), of pulmonary embohsm (relative risk 3 0), and of
deep vein thrombosis (relative risk l 6) 151 Another placebo-
controlled trial with tamoxifen m hysterectomized women
also showed an incieased nsk of venous thrombosis, includ-
ing superficial thrombophlebitis 1S2 In a randomized trial of
breast cancer prevention, raloxifene increased the risk of
venous thrombosis 3-foldm In a case-control study
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of tamoxifen use for breast cancer treatment, it was shown to
increase venous thrombotic nsk 7-fold 154 These studies
convmcmgly show that currently used selective estrogen
receptor modulators increase the nsk of thrombosis
Clinical Implications
Although many aspects of the thrombotic risks associated
with female hormones are only just emergmg, some clmical
implications seem evident First, m the choice of contracep-
tion, a personal history of thrombosis needs to be taken into
account The nsk of thrombotic disease can be limited by
considenng other types of contraception in women with a
personal history of thrombosis, a family history of thrombo-
sis, gross obesity, and major cardiovascular nsk factors A
contracepüve with 30 μg ethmyl estradiol should be the first
choice, but there is httle Information that would favor the use
of oral contraceptives with a lower dose of estrogen Oral
contraceptives contaming third-generation progestogens, le,
desogestrel or gestodene, should be avoided because of the
increased nsk of venous thrombosis Especially in smokers,
oral contraceptives should not be contmued beyond the 35th
year of age because of the increased nsk of artenal disease
Indiscnmmate screening for prothrombotic mutations before
the prescnption of oral contraceptives is unlikely to be cost
effective or even to have a positive nsk-benefit balance 155156
It is currently unclear whether screening in the presence of a
positive family history should be preferred over alternative
contraception in all those women.
The best currently avaüable data for postmenopausal hor-
mone replacement do not support a cardiovascular benefit.
The route of admimstration (oral or transdermal) does not
matenally affect the nsk of side effects Therefore, hormonal
replacement therapy should not be prescnbed for the preven-
tion of cardiovascular disease, and short-term prescnption for
relief of menopausal Symptoms should be the mam indica-
tion A recent Statement from the Amencan Heart Association
also urges caution m the prescnption of postmenopausal
hormones 157 Hormone replacement should be avoided in
women with a personal or family history of venous
thrombosis
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